<DOC>
	<DOCNO>NCT02254798</DOCNO>
	<brief_summary>Validation already describe biomarkers acute GVHD prediction severity Fecal calprotectin alpha 1 anti-trypsin , plasmatic RER3a , IL-8 , Elafin , TNFaR1 , IL-2R alpha , HGF</brief_summary>
	<brief_title>Biomarkers Acute Graft-versus-host Disease</brief_title>
	<detailed_description>Description project : The main objective prospective biological single center study ( non interventional ) identify non invasive biomarkers able diagnose acute GVHD and/or predict outcome patient acute GVHD . The primary objective study double : ( 1 ) : evaluate marker diagnostic marker GVHD ( 2 ) : evaluate potential marker risk factor steroid-refractory acute GVHD occurrence . Secondary objective : -to evaluate marker risk factor GVHD -to evaluate potential marker prognostic factor 6-month non-relapse mortality patient acute GVHD-to evaluate additional value biomarkers predict GVHD steroid-refractory GVHD compare know routinely use risk factor ( clinical grading system , performance status , albuminemia ... ) . Stools blood day 7 , 14 , 21 , 28 transplantation first day digestive GVHD . Management patient differ usual care . Fecal calprotectin alpha 1 anti-trypsin , plasmatic RER3a , IL-8 , Elafin , TNFaR1 , IL-2R alpha , HGF measure point ELISA test . 315 patient would sufficient estimate area ROC curve half-width 99 % confidence interval 0.05 , assume 60 % patient would develop acute GVHD , normally distributed marker . The diagnosis prognosis value analyze separately . Expected result : If biomarkers find significantly associate diagnosis prognosis acute GVHD , compare current clinical , biological histological marker . Indeed , marker clinical potential impact give similar good information routine currently available marker , ie : clinical GVHD grading system , performance status , gut endoscopy histology . The non-invasivity biomarkers also take account ( comparison histology ) . Identification diagnostic marker avoid useless treatment high dose corticosteroid patient without GVHD Identification prognostic marker comfort decision second-line treatment sooner usually , ie : GVHD onset . Indeed , onset second-line treatment steroid-refractory GVHD vary 3 21 day depend clinical evolution patient . If prognostic marker available diagnosis , delay second-line treatment shorten patient consequently increase chance response early treatment . Identification prognostic marker also guide corticosteroid decrease patient good prognosis GVHD</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>adult patient receive allogeneic transplant inform consent sign patient refusal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>